
With a $49.24 million market cap, Minerva Neurosciences Inc. (NERV) is a clinical-stage biopharmaceutical company that develops drug candidates for the treatment of central nervous system (CNS) diseases.
The company’s lead candidates include roluperidone to treat schizophrenia and MIN-301 for treating Parkinson’s and other neurodegenerative disorders.